To include your compound in the COVID-19 Resource Center, submit it here.

bluebird, TC BioPharm in gamma delta CAR T deal

bluebird bio Inc. (NASDAQ:BLUE) and TC BioPharm Ltd. (Edinburgh, U.K.) partnered on Dec. 7 to discover and develop gamma delta chimeric antigen receptor (CAR) T cells to treat hematologic malignancies and solid tumors using

Read the full 347 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers